首页 > 市场调查报告书 > 製药

生物製剂分子标靶治疗学

市场调查报告书

商品编码

1526806

抗TIGIT抗体市场:临床试验与市场机会预测:2028年

Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028

出版日期: 2024年08月01日 | 出版商:

KuicK Research | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

抗TIGIT抗体已成为癌症免疫治疗中一种有前途的方法，为各种癌症类型，特别是实体瘤患者带来新的希望。 TIGIT（具有 Ig 和 ITIM 结构域的 T 细胞免疫受体）是 T 细胞和自然杀手 (NK) 细胞上表达的抑制性受体，在调节免疫反应中发挥重要作用。标靶 TIGIT 可以增强免疫系统识别和消除癌细胞的能力，从而可能彻底改变癌症治疗策略。

TIGIT 作为癌症免疫治疗标靶的治疗潜力在于其作为免疫检查点分子的功能。当 TIGIT 与 CD155 和 CD112 等配体相互作用时，它可能会抑制 T 细胞和 NK 细胞的激活，从而使癌细胞逃避免疫监视。透过使用抗 TIGIT 治疗方法阻断这种相互作用，研究人员希望重新激活针对肿瘤的免疫反应并改善癌症患者的临床结果。

在针对 TIGIT 的各种方法中，单株抗体已成为使用最广泛和最有前途的药物。这些抗体被设计为特异性结合 TIGIT，抑制其与其配体的相互作用并释放免疫系统中的 "断开" 。抗体的高特异性和相对低的毒性使其成为临床开发的有吸引力的候选者。

抗 TIGIT 抗体的开发进展迅速，目前有 50 多个候选抗体处于临床开发阶段。这条强大的产品线支持了这种方法在癌症治疗中的巨大兴趣和潜力。其中，超过5种抗TIGIT抗体已进入3期临床试验，这是监管部门批准前临床开发的最高级阶段。其中包括分别由医药标记物领导者默克基因泰克和百济神州开发的vivostlimab、tiragolumab和ocipelilimab。

本报告提供全球抗TIGIT抗体市场相关调查，提供市场概要，以及抗TIGIT抗体的临床实验平台，各适应症，各国趋势，及市场参与市场企业的竞争趋势等资讯。

Anti TIGIT Antibodies In Clinical Trials: > 50 Antibodies
First Anti TIGIT Antibody To Get Approval Within Next 5 Years
Global Anti TIGIT Antibodies Clinical Pipeline Insight By Company, Indication and Phase
Insight On More Than 50 Anti TIGIT Antibodies In Clinical Trials
Anti TIGIT Antibodies Market Trends by Indication & Country
Global Anti TIGIT Antibodies Market Dynamics

Anti TIGIT antibodies have emerged a promising approach in cancer immunotherapy, offering new hope for patients with various types of cancers, particularly solid cancers. TIGIT (T cell immunoreceptor with Ig and ITIM domains) is an inhibitory receptor expressed on T cells and natural killer (NK) cells, playing a crucial role in modulating immune responses. By targeting TIGIT, researchers aim to enhance the immune system's ability to recognize and eliminate cancer cells, potentially revolutionizing cancer treatment strategies.

The therapeutic potential of TIGIT as a target for cancer immunotherapy lies in its function as an immune checkpoint molecule. When TIGIT interacts with its ligands, such as CD155 and CD112, it suppresses T cell sand NK cell activation, potentially allowing cancer cells to evade immune surveillance. By blocking this interaction with anti-TIGIT therapeutic approaches, researchers hope to reinvigorate the immune response against tumors, leading to improved clinical outcome for cancer patients.

Among the various approaches for targeting TIGIT, monoclonal antibodies have emerged as the most widely used and promising agents. These antibodies are designed to specifically bind to TIGIT, preventing its interaction with its ligands and thus releasing the "breaks" on the immune system. Their high specificity and relatively low toxicity of antibodies make them attractive candidates for clinical development.

The field of anti-TIGIT antibody development has seen rapid progress, with over 50 candidates currently in clinical development. This robust pipeline underscores the significant interest and potential of this approach in cancer treatment. Among these, more than five anti TIGIT antibodies have advanced to phase 3 clinical trials, representing the most advanced stage of clinical development before potential regulatory approval. These include Vibostolimab, Tiragolumab and Ociperlimab, developed by the pharmaceutical marker leaders, Merck Genentech and BeiGene, respectively.

These phase 3 clinical trials are assessing the safety and efficacy of these anti-TIGIT antibodies in various cancer types, with a particular focus on non-small cell lung cancer (NSCLC). The emphasis on NSCLC is not surprising, given its high prevalence and the need for more effective treatment options. NSCLC represents a significant portion of lung cancer cases and has shown promising responses to immunotherapy approaches in the past.

Several key factors are driving the market potential of anti-TIGIT antibodies. Firstly, there remains a substantial unmet medical need in cancer treatment, especially for patients who do not respond to or develop resistance to existing immunotherapies. Anti-TIGIT antibodies offer a novel mechanism of action that could address these challenges. Moreover, these antibodies show promising results in combination with established therapies like PD-1/L1 inhibitors, potentially expanding the market for both drug classes and improving treatment outcomes. This becomes visible in Merck's vision of developing a coformulation of its anti-TIGIT antibody Vibostolimab with its blockbuster anti-PD-1 antibody pembrolizumab for the treatment of various solid tumors.

The broad applicability of anti-TIGIT antibodies across various cancer forms presents another significant market opportunity. While a majority of clinical trials currently focus on NSCLC, many other ongoing clinical trials are exploring their efficacy in other solid cancers tumors and hematological malignancies, which could lead to multiple approved indications, consequently increasing the anti-TIGIT antibody market size.

As evident from the examples above, the competitive landscape for the anti-TIGIT antibody market is dynamic, with major pharmaceutical companies and biotechnology firms vying for market share. While Vibostolimab leverages the company's strong position in the immuno-oncology market, another, Domvanalimab, being developed by Gilead Sciences and Arcus Biosciences, benefits from a partnership between a major pharmaceutical company and a competent biopharmaceutical company.

In conclusion, anti-TIGIT antibodies not only represent a significant advancement in cancer immunotherapy, but also present many opportunities for drug development and market expansion. With its potential to address unmet medical needs, broad applicability and alignment with personalized medicine, this emerging class of drugs is poised to capture a substantial portion of cancer immunotherapy market.

1. Introduction to Anti TIGIT Antibody

1.1 Overview
1.2 Mechanism of Anti TIGIT Antibodies
1.3 Clinical Approaches to Target TIGIT

2. Global Anti TIGIT Antibodies Clinical Trials Overview

2.1 By Company
2.2 By Country
2.3 By Indication
2.4 By Patient Segment
2.5 By Phase

3. Global Anti TIGIT Antibodies Clinical Pipeline By Company, Indication and Phase

3.1 Research
3.2 Preclinical
3.3 Phase I
3.4 Phase I/II
3.5 Phase II
3.6 Phase III

4. Global Anti TIGIT Antibodies Market Outlook

4.1 Current Clinical & Market Trends
4.2 Future Market Outlook

5. Anti TIGIT Antibodies Market Trends by Indication

5.1 Cancer
5.2 Autoimmune & Inflammatory Disorders
5.3 Microbial Infections

6. Anti TIGIT Antibodies Market By Country

6.1 US
6.2 China
6.3 South Korea
6.4 Australia
6.5 UK

7. Combinations Approaches for TIGIT Therapy

8. TIGIT Co Inhibition with PD1 or PDL1

9. Global Anti TIGIT Antibodies Market Dynamics

9.1 Market Drivers
9.2 Commercialization Challenges

10. Competitive Landscape

10.1 Akeso Biopharma
10.2 BeiGene
10.3 Bio-Thera Solutions
10.4 Biotheus
10.5 Compugen
10.6 FutureGen Biopharmaceutical
10.7 Merck Sharp & Dohme
10.8 Nanjing Sanhome Pharmaceutical
10.9 OriCell Therapeutics
10.10 Phio Pharmaceuticals
10.11 Roche
10.12 Shanghai Henlius Biotech
10.13 Shanghai Junshi Biosciences
10.14 Simcere Pharmaceutical Group
10.15 Tasrif Pharmaceutical

简介目录图表

List of Figures

Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
Figure 1-2: TIGIT Inhibitor - Proposed Mechanism of Action

Figure 1*3: TIGIT Inhibitor - Mechanism of Action

Figure 1-4: Binding Efficacy of Monoclonal Antibody
Figure 1-5: Binding Efficacy of Bispecific Antibodies
Figure 1-6: Advantages of Small Molecule Drugs over Therapeutic Antibodies
Figure 2-1: Global - Anti TIGIT Antibodies Clinical Trials by Company (Number of Drugs), 2024 -2028
Figure 2-2: Global - Anti TIGIT Antibodies Clinical Trials by Country (Number of Drugs), 2024 - 2028
Figure 2-3: Global - Anti TIGIT Antibodies Clinical Trials by Indication (Number of Drugs), 2024 - 2028
Figure 2-4: Global - Anti TIGIT Antibodies Clinical Trials by Patient Segment (Number of Drugs), 2024 - 2028
Figure 2-5: Global - Anti TIGIT Antibodies Clinical Trials by Phase (Number of Drugs), 2024 -2028

Figure 4 1: Global TIGIT Therapy Fundamental Companies

Figure 4 2: Future TIGIT Market

Figure 5-1: Anti-LAG-3 (BMS-986016) & Anti-TIGIT (BMS-986207) Phase I/II (NCT04150965) Study - Initiation & Completion Year
Figure 5-2: Compugen TIGIT Antibody Cancer Pipeline
Figure 5-3: Keio University School of Medicine Research Study
Figure 5-4: University of Zurich Investigation for TIGIT Antibody to Cure Viral Infection
Figure 5-5: Combination TIGIT Therapy for Viral Infections
Figure 6-1: PD-1 Inhibitor Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) Phase II (NCT05130177) Study - Initiation & Completion Year
Figure 6-2: iTeos Therapeutics & GSK Triumph Enrolment Milestone
Figure 6-3: Bristol Myers Squibb & Agenus Preclinical Candidates, BMS-986442
Figure 6-4: Clinical TIGIT Therapy Pipeline in China
Figure 6-5: JS006 Monotherapy and in Combination With Toripalimab Phase I (NCT05061628) Study - Initiation & Completion Year
Figure 6-6: Chinese Companies TIGIT Candidates Insights
Figure 6-7: Zimberelimab with Domvanalimab Phase II (NCT04262856) Study - Initiation & Completion Year
Figure 6-8: Aspects Influencing South Korea TIGIT Market
Figure 6-9: HLX301 Phase I/II (NCT05102214) Study - Initiation & Completion Year
Figure 6-10: AZD8205 Monotherapy or in Combination with Anticancer Drugs Phase I/II (NCT05123482) Study - Initiation & Completion Year
Figure 6-11: Key Players in UK TIGIT Market
Figure 7-1: TIGIT Therapy Combinations
Figure 9-1: Global - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-2: TIGIT Inhibitor Market Drivers
Figure 9-3: Stages of Drug Development

List of Tables

Table 1-1: Anti-TIGIT Monoclonal Antibodies in Development
Table 5-1: Ongoing Cancers Clinical Trials for TIGIT Therapy
Table 6-1: Ongoing US Clinical Trials for TIGIT Therapy
Table 6-2: Ongoing China Clinical Trials for TIGIT Therapy
Table 7-1: Ongoing Preclinical & Clinical Trials for Combination of TIGIT inhibitors

02-2729-4219

+886-2-2729-4219

License/价格

抗TIGIT抗体市场:临床试验与市场机会预测:2028年

Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028

目录

第1章抗TIGIT抗体的简介

第2章全球抗TIGIT抗体临床试验概要

第3章企业，适应症，各相的全球抗TIGIT抗体的临床实验平台

第4章全球抗TIGIT抗体市场预测

第5章抗TIGIT抗体的市场趋势，各适应症

第6章抗TIGIT抗体市场，各国

第7章 TIGIT疗法的复合方法

第8章 TIGIT和PD1或PDL1共阻碍

第9章全球抗TIGIT抗体市场动态

第10章竞争情形